| Trial ID: | L5845 |
| Source ID: | NCT00486187
|
| Associated Drug: |
Rosiglitazone
|
| Title: |
Effects of ROSIglitazone on Inflammatory Markers and Adipokines in Diabetic Patients Using an Angiotensin Receptor Blocker (TELmisartan) - The ROSITEL Study
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 2 Diabetes Mellitus
|
| Interventions: |
DRUG: rosiglitazone|DRUG: metformin or sulfonylurea
|
| Outcome Measures: |
Primary: Change in adiponectin level in the rosiglitazone vs. metformin/sulfonylurea arms, 12 weeks | Secondary: Secondary end-points include changes in leptin, resistin, hs-CRP, IL-6, MMP-9, ICAM-1, insulin sensitivity (as estimated by the HOMA technique), HbA1c, and lipid levels in the rosiglitazone vs. metformin/sulfonylurea arms, 12 weeks
|
| Sponsor/Collaborators: |
Sponsor: Dr. Milan Gupta | Collaborators: GlaxoSmithKline
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
103
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2006-04
|
| Completion Date: |
2009-06
|
| Results First Posted: |
|
| Last Update Posted: |
2016-01-28
|
| Locations: |
Partners Research, Brampton, Ontario, L6V 1B4, Canada
|
| URL: |
https://clinicaltrials.gov/show/NCT00486187
|
